Prognosis 2025: Hits, Misses & What We’re Betting on for 2026

Season 3 of the Fuller Butz Podcast opens with a comprehensive look back at our 2025 predictions, separating what truly moved the needle in plastic surgery from what failed to gain traction. This “Wrapped” episode serves as both a retrospective and a roadmap, grounded in real-world clinical experience, patient outcomes, and evolving technology.

We begin by revisiting one of our most confident and ultimately successful predictions: the launch of the FDA-approved Motiva breast implant. Throughout 2024, we discussed the growing momentum behind Motiva’s design philosophy, data-driven development, and global track record. In 2025, that prediction came to fruition with FDA approval, and its entry into the U.S. market has already begun reshaping conversations around implant technology, safety, and patient choice. We break down what makes Motiva different, from surface technology to consistency and responsiveness, and discuss how FDA approval validates years of international data. More importantly, we explore how this approval expands options for patients seeking a more natural feel and long-term reliability, while raising the bar for innovation across the implant space.

Another major “hit” from our 2025 forecast was the continued success and broader adoption of the internal bra. Once viewed as a niche adjunct, internal bra technology has become a mainstay in breast surgery for surgeons focused on long-term shape, support, and durability of results. We discuss how internal bra use has matured from early experimentation into refined technique selection, improved materials, and clearer indications. From revision cases to primary lifts and augmentations, internal bra support has proven its value in reducing bottoming out, improving upper pole stability, and enhancing longevity. 

Not every prediction, however, came to pass. We take an honest look at AlloClae, a product we believed might gain stronger momentum in 2025. Despite theoretical advantages and early interest, AlloClae did not achieve widespread adoption or consistent clinical enthusiasm. We discuss possible reasons, including cost, handling characteristics, outcome variability, and surgeon preference, emphasizing why it’s important to continually reassess emerging technologies against real-world performance. This segment underscores a recurring theme of the episode: innovation alone is not enough. Adoption depends on reliability, reproducibility, and clear benefit to both surgeon and patient.

Looking ahead, we turn our attention to 2026 predictions, starting with the Preserve system from Motiva. We discuss why Preserve represents a potential next evolution in breast implant surgery, focusing on tissue preservation, surgical planning, and alignment with modern patient priorities. 

Beyond devices and implants, we expand the conversation to areas we believe will see significant advancement in 2026: compression garments, postoperative care, and nutrition. We predict a move toward smarter, more patient-specific compression solutions that improve comfort while maintaining effectiveness. In postop care, we anticipate greater integration of multimodal recovery strategies, emphasizing mobility, lymphatic support, and data-driven protocols. 

This episode sets the tone for Season 3 by reinforcing what the Fuller Butz Podcast does best: thoughtful analysis, honest reflection, and forward-thinking discussion grounded in real practice. As we close the chapter on 2025 and look ahead to 2026, the message is clear. Progress in plastic surgery is rarely about a single breakthrough. It’s about consistent refinement, better decision-making, and putting patient outcomes at the center of every prediction and every procedure.

https://myquintessa.com/staff/dr-daniel-butz/

https://samfullerplasticsurgery.com/